MTP - Midatech Pharma Plc

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.775
+0.040 (+5.44%)
At close: 2:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.735
Open0.786
Bid0.500 x 4000
Ask1.000 x 800
Day's Range0.710 - 0.788
52 Week Range0.450 - 2.650
Volume18,202
Avg. Volume43,329
Market Cap24.962M
Beta0.13
PE Ratio (TTM)N/A
EPS (TTM)-0.828
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Who Are Midatech Pharma Plc’s (LON:MTPH) Major Shareholders?
    Simply Wall St.5 days ago

    Who Are Midatech Pharma Plc’s (LON:MTPH) Major Shareholders?

    If you want to know who really controls Midatech Pharma Plc (LON:MTPH), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock inRead More...

  • Zacks Small Cap Research16 days ago

    MTP: Positive Interim Results for MTD201 Proof-of-Concept Study…

    Midatech Pharma Plc (MTP) is a specialty pharmaceutical company with three novel drug delivery technologies that improve bio-distribution and bio-delivery of drugs. The technologies are designed to enable the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs. The gold nanoparticle (GNP) technology platform is based on GNP drug conjugates, which at 2 nm are among the smallest particles in biomedical use.

  • GlobeNewswire23 days ago

    Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera™ Microsphere Technology

    Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera™ Microsphere Technology. Interim data for key oncology drug candidate MTD201 ...

  • GlobeNewswire2 months ago

    Midatech Pharma PLC: Trading Update

    Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, today announces a trading update for the six months ended 30 June 2018. The Company remains on track to deliver financial results in line with market expectations for FY18. For the six months to June 2018, the Board expects total gross product revenues of approximately £5.8 million, a 16% increase from the £5.0 million recorded in the six months to June 2017.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Hasbro, Inc. (NASDAQ: HAS ) stock gained more than ...

  • GlobeNewswire2 months ago

    Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal® to the Oncology Market in United States

    Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, today announces that its US subsidiary, Midatech Pharma US Inc., has signed a co-promotion agreement with an affiliate of Bausch Health Companies Inc. (“Bausch Health”) that provides Midatech with the exclusive rights to promote Bausch Health’s supersaturated calcium product NeutraSal® in the oncology market in the United States. In exchange for its promotional efforts, Midatech will receive a percentage of the net sales of NeutraSal resulting from prescriptions generated at oncology practices throughout the United States.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics

    NEW YORK, NY / ACCESSWIRE / May 3, 2018 / There was no catalyst or news to send shares of both Midatech and Eleven Biotherapeutics higher on Wednesday. Midatech Pharma Plc shares closed up 10.56% yesterday with more gains seen in after-hours trading as well. There was no significant news from the specialty pharmaceutical company to explain the move up.

  • Zacks Small Cap Research5 months ago

    MTP: Midatech Targeting $2 Billion Market Opportunity with MTD201

    Midatech Pharma Plc (MTP) is a specialty pharmaceutical company with three novel drug delivery technologies. The technologies are designed to enable the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs. The gold nanoparticle (GNP) technology platform is based on GNP drug conjugates, which at 2 nm are among the smallest particles in biomedical use.

  • Where Münchener Tierpark Hellabrunn AG’s (MUN:MTP) Earnings Growth Stands Against Its Industry
    Simply Wall St.6 months ago

    Where Münchener Tierpark Hellabrunn AG’s (MUN:MTP) Earnings Growth Stands Against Its Industry

    Examining how Münchener Tierpark Hellabrunn AG (MUN:MTP) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple senseRead More...

  • Zacks Small Cap Research7 months ago

    MTP: Lead Candidates Set to Enter the Clinic; U.S. Product Sales Up ~30% in 2017

    On January 16, 2018, Midatech Pharma Plc (MTP) announced that the U.S. Food and Drug Administration (FDA) approved the investigational new drug (IND) application to initiate a clinical trial of MTX110 in patients with diffuse intrinsic pontine glioma (DIPG). The active compound in MTX110 is the poorly soluble hydroxamic acid drug panobinostat, a histone deacetylase inhibitor (HDACi), which until recently could not be formulated for parenteral administration.

  • Zacks Small Cap Research8 months ago

    MTP: Receives Approval to Initiate First In Human Trial of Q-Octreotide (MTD201); Four Year Loan Agreement with MidCap Financial

    On January 9, 2018, Midatech Pharma Plc (MTP) announced that Polish regulators have given approval to initiate the company’s first in-human clinical trial of Q-Octreotide (MTD201). Q-Octreotide is the sustained release (SR) version of octreotide, an octapeptide that mimics naturally occurring somatostatin. Octreotide is an existing, immediate- and sustained- release injection product used to decrease the production of growth hormone in people suffering from acromegaly and for the treatment of neuroendocrine (hormone secreting) tumors (NET).

  • Zacks Small Cap Research10 months ago

    Initiating Coverage of Midatech Pharma (MTP); Novel Nanotechnology Platforms Focused on Oncology and Other Therapeutic Areas

    We are initiating coverage of Midatech Pharma Plc (NASDAQ:PLC) with a $6.00 valuation. MIdatech is a U.K. based international specialty pharmaceutical company focused on oncology and other therapeutic areas. The company has three proprietary drug delivery technologies: Q-Sphera for sustained release of already marketed products, Midacore gold nanoparticles (GNP) for targeted delivery, and Nano Inclusion (NI) for local delivery.

  • Is Midatech Pharma Plc (AIM:MTPH) Undervalued?
    Simply Wall St.11 months ago

    Is Midatech Pharma Plc (AIM:MTPH) Undervalued?

    Midatech Pharma Plc (AIM:MTPH), a biotechnology company based in United Kingdom, saw significant share price volatility over the past couple of months on the AIM, rising to the highs ofRead More...